Nicotinamide adenine dinucleotide, a coenzyme critical for cellular energy metabolism that declines with age. NAD+ precursors like NMN and NR are studied as longevity interventions.

Mechanistic target of rapamycin, a key nutrient-sensing pathway that regulates cell growth and aging. Inhibiting mTOR (e.g., with rapamycin) has shown lifespan extension in multiple organisms.

A class of drugs that selectively eliminate senescent (aged, dysfunctional) cells to reduce inflammation and improve tissue function.

What is Epigenetic clock?

A biomarker based on DNA methylation patterns that estimates biological age, often more predictive of health outcomes than chronological age.

The period of life spent in good health, free from chronic diseases and disability associated with aging.

An immunosuppressant drug that inhibits the mTOR pathway. Research shows rapamycin may extend lifespan and improve age-related health outcomes in multiple species.

What is Biological age?

A measure of how well or poorly your body is functioning relative to your chronological age, assessed through biomarkers such as DNA methylation, telomere length, and blood panels.

What is Caloric restriction?

A dietary regimen that reduces calorie intake without malnutrition. Caloric restriction is one of the most studied interventions shown to extend lifespan across species.

Protective caps at the ends of chromosomes that shorten with each cell division. Telomere length is associated with aging and age-related diseases.

A state in which cells permanently stop dividing but resist death, accumulating with age and secreting inflammatory factors that damage surrounding tissue.

A second-generation epigenetic clock that predicts time to death and is considered one of the most accurate measures of biological aging.

What is Inflammaging?

Chronic, low-grade inflammation that increases with age and contributes to the development of age-related diseases including cardiovascular disease, diabetes, and neurodegeneration.

The large-scale study of proteins in biological systems. In longevity research, proteomics identifies blood protein signatures that predict biological age and disease risk.

What is Yamanaka factors?

A set of four transcription factors (Oct4, Sox2, Klf4, c-Myc) that can reprogram adult cells to a pluripotent state. Partial reprogramming with Yamanaka factors is being explored to reverse cellular aging.

Nicotinamide mononucleotide, a precursor to NAD+ that is widely studied as a supplement to boost cellular energy and combat age-related decline.

A gene-editing technology that allows precise modifications to DNA. In longevity research, CRISPR is used to study and potentially modify genes associated with aging.

Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026

Intellia Therapeutics has announced the upcoming topline clinical data from its Phase 3 HAELO trial for lonvoguran ziclumeran (lonvo-z), a CRISPR gene editing candidate targeting hereditary angioedema (HAE). This marks a significant milestone as it represents the first Phase 3 readout for an in vivo CRISPR gene editing therapy, highlighting the potential of gene editing technologies in treating genetic disorders. The data will be presented during a webcast on April 27, 2026, at 8:00 a.m. ET.

The significance of this trial lies in its potential to redefine treatment paradigms for HAE, a severe genetic condition characterized by recurrent episodes of swelling. By utilizing CRISPR technology, lonvo-z aims to address the underlying genetic causes of the disease, potentially offering a curative approach rather than symptomatic relief. The success of this trial could pave the way for broader applications of CRISPR in other genetic disorders, reinforcing the therapeutic viability of gene editing.

The implications of this development extend beyond HAE treatment; it could accelerate the integration of CRISPR technologies into clinical practice. As the first Phase 3 data emerges, it may influence regulatory pathways and funding priorities for gene editing therapies, thereby reshaping timelines for drug development in the field of genetic medicine. This could lead to a faster transition from research to clinical application, ultimately enhancing the landscape of treatments available for a variety of genetic conditions.

Source: globenewswire.com